ORGANIZATION AND MANAGEMENT
The Bantam management team has extensive leadership experience and proven records in oncology drug discovery and development for bio-pharmaceuticals.
HIGHLIGHTS
Founded 2015
Novel mechanism of action
Patented Technology
SCIENCE ADVISORY BOARD
Prominent industry and academic leaders in oncology drug development and leadership roles
EXPERIENCED TEAM
Deep experience in oncology drug discovery and development
MARKET
$10 billion oncology market opportunity
Bantam operates as a virtual company in a highly cost efficient manner. The Bantam management team has deep experience in oncology drug discovery and development including R&D and partnering. Bantam’s scientific advisory board is comprised of prominent academic and industry leaders with drug development and executive leadership roles in early stage and global pharmaceutical companies.
MANAGEMENT TEAM
MICHAEL LUTHER, PhD, MBA
President & CEO
- Former VP drug discovery for both GSK and Merck
- At GSK and Merck, led teams that progressed new medicines from bench to clinic
- Experience includes strong operations and business development experience in startups and global biopharmaceutical industry
MATTHEW KOSTURA, PhD
Chief Scientific Officer
- Deep drug discovery experience from target validation to proof of concept
- Includes scientific and management roles in pharma and biotech organizations including Merck, GSK, and TransTech Pharma
ALAN COOPER, PhD
Head of Chemistry
- Medicinal chemist with extensive experience in drug discovery and development at Schering-Plough and Merck
- Participated in the discovery of several marketed drugs including Noxafil®, and Lonafarnib®
- Expertise in oncology, antibacterial, antiviral, and immunology drug discovery
ANIL K. GOYAL, PhD, CLP
Chief Business Officer
- 23+ years business development and leadership roles in several public and private biotech companies
- Strategic approach and experience in creative deal making, M&A, in/out-licensing and acquisition/exits
- Fund raising from VC, Corp VC, public market, NIH and venture philanthropies
BOARD OF DIRECTORS
Michael Luther, PhD, MBA,
President, CEO
Bantam Pharmaceutical
Lionel Goldfrank III
Principal in several private investment companies
Founder of American & Overseas Asset Services Corporation
Formerly with Goldman Sachs
Victor Keen
Of Counsel at Duane Morris, LLP
Co-Chair Caretec Group, Inc (OTC)
Former Board Member Research Frontiers, Inc (NASD)
W. James Tozer, Jr.
Co-owner and Founder Vectra Management Group
Former Senior Executive Citicorp and
President of Prudential Securities
Founding Investor in LendingTree, Vectra Bank Colorado,
and Draper Bank
Bio-Tech Venture Investor in GangaGen, Iveena, PenBlade
and PhotoPharmics
SCIENCE ADVISORY BOARD
Briggs Morrison, MD
Managing Partner MPM Capital,
CEO Syndax, Inc.
Mike Patane, PhD
CEO, Mitobridge
Rainer Fuchs, PhD
Former CIO Harvard Medical School
Biogen & GSK R&D;
Joshua Rabinowitz, MD, PhD
Professor, Princeton University
Nahum Sonenberg, PhD
Professor, Goodman Cancer Research Centre, McGill University
George Mulligan, PhD
VP Translational Medicine Mitobridge
Mark Manfredi, PhD
CEO, Kyn Therapeutics
EIR Atlas Venture
Jedd Levine, MD, MBA
EVP Clinical Affairs, Oncology Partners